2023-510307-22-00招募中1 期
A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.17 个研究点 分布在 7 个国家目标入组 116 人开始时间: 2024年3月11日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 116
- 试验地点
- 17
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
CT Disclosure & Data Transparency
Scientific
Boehringer Ingelheim International GmbH
研究点 (17)
Loading locations...
相似试验
已完成
1 期
A study to find a suitable dose of BI 1821736 and test whether it helps people with advanced cancer2022-502125-17-00Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.14
招募中
1 期
A study to test different doses of BI 764532 in patients with small cell lung cancer and other neuroendocrine tumours that are positive for DLL3.2024-513100-34-00Boehringer Ingelheim International GmbH129
已完成
1 期
A study in healthy men to test how BI 1291583 is processed in the body2022-502264-20-00Boehringer Ingelheim International GmbH8
招募中
不适用
A study to test BI 765179 alone and in combination with ezabenlimab in patients with advanced cancer (solid tumors) and BI 765179 in combination with pembrolizumab in patients with advanced head and neck cancerjRCT2031210652Boehringer Ingelheim127
招募中
1 期
A study to test whether BI 456906 (survodutide) influences the amount of bupropion, caffeine and midazolam in the blood in people with overweight or obesityObesity2024-512332-29-00Boehringer Ingelheim International GmbH30